KMD Bioscience Co., Ltd.
400-621-6806
Service Line：+1-315-239-3085
Address：FL-4, Building A5, International Enterprise Community, Tianjin, China
Email：info@kmdbioscience.com
| Catalog Number | COP105 |
|---|---|
| Product Name | Beta (B.1.351) SARS-CoV-2 Spike d19 |
| Molecular Name | Spike |
| Size | 100ul,500ul,1ml |
| Species | SARS-CoV-2 |
| Host | 293T cell |
| Applications | Neutralizing antibody/serum test |
| Backbone | HIV-1 |
| Titer | >10^3 TCID50/mL |
| Envelope protein | Beta (B.1.351) SARS-CoV-2 Spike protein |
| Background | The Beta variant of COVID-19 (B.1.351) was first identified in South Africa in December 2020. There are eight major mutations in the Spike protein, including three important mutations in RBD: K471N, E484K and N501Y, among which E484K and N501Y are located in the receptor binding region, which is the main site of binding to human ACE2 receptor. The team found that both the mRNA and recombinant protein vaccines were less protective against the Beta variant. 293T cells were transfected with HIV-1 (human immunodeficiency virus type I) -based vector and packaged into SARS-CoV-2 (2019-nCoV) (B.1.351) Spike pseudovirus. It can be used to infect cells overexpressing ACE2. This pseudovirus has no self-replication ability, and has the characteristics of high safety and operability. |
| Storage | Store at -80℃. Avoid freeze-thaw cycles. |
| Shipping Condition | Shipped on dry ice packs. |
| Note | Recommended for use in BSL-2 grade laboratories. This product is used for research use only. Not for human or diagnostic use. |
FL-4, Building A5, International Enterprise Community, Tianjin, China
Email：info@kmdbioscience.com
Hot Line： +1-315-239-3085
Technical Support：sales@kmdbiosci.com
